LY451395

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

Alzheimer's Disease

Phase 2

Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

CompletedNCT00051909

Eli Lilly and CompanyAlzheimer's Disease

Start: 2002-11-30End: 2003-06-30Target: 200Updated: 2006-07-19

Treatment for Aggression and Agitation in Patients With Alzheimer's Disease

CompletedNCT00843518

Eli Lilly and CompanyAlzheimer's Disease

Start: 2009-02-28End: 2011-06-30Updated: 2017-11-29

Related Papers

Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease.

2012-12-2141 citations